Strategic partnerships StemBioSys collaborates closely with The University of Texas Health Science Center San Antonio and has completed a cGMP facility build with BioBridge Global, signaling readiness for partnered manufacturing and translational collaborations in cell culture and therapeutic development.

Therapeutic expansion Beyond research tools, the company is exploring therapeutic applications of CELLvo Matrix and next generation products, presenting upsell opportunities to contract development, manufacturing, and clinical collaboration partners seeking scalable stem cell culture platforms.

Targeted product launches Recent launches include chamber-specific hiPSC-derived cardiomyocytes and the CELLvo atrial cardiomyocyte, indicating a pattern of expanding the catalog for disease modeling, drug screening, and potentially regenerative medicine partners.

SBIR funded validation A $300K SBIR grant from NIDDK supports ECM-based culture system development, providing third-party validation and a potential entry point for government-funded projects or collaborations with researchers focusing on islet procurement and immunogenicity reduction.

Scaleable platform focus With a core patented CELLvo Matrix platform and ongoing scale-up activities, there are opportunities to offer process development, GMP-compliant manufacturing services, and turnkey cell culture solutions to biotech firms needing reliable, scalable stem cell culture infrastructure.